Product information and disease descriptionProduct descriptionProduct information
Contraindications/Warnings/Precautions/Adverse effects
8 evidence topics · 8 sources
Warnings and precautions
FDA written feedback on antinuclear antibody testing and the autoimmune risk description
Antinuclear antibody seroconversion: phase 2 randomized period
| Measure | Placebo (N=22) | Claseprubart 300mg/2mL Q2W (N=21) | Claseprubart 600mg/4mL Q2W (N=22) |
|---|---|---|---|
| Newly positive for anti-nuclear antibodies (ANA) | “0 (0%)” | “1 (5.9%)” | “8 (36.4%)” |
| Rashes | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Arthralgia | “1 (4.5%)” | “1 (4.8%)” | “0 (0%)” |